Trial Information - Phase III
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer
Protocol ID: 67652000PCR3002
Sponsor: Janssen Research & Development, LLC
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
